AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02608736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The other half of the participants will receive placebo for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in valproic acid arm.
Trial: NCT03790709
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT03508947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride
Trial: NCT02383511
Drug: SMT C1100
RxNorm normalized name: ZINC OXIDE 2.94 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g / OCTINOXATE 7 g in 100 g TOPICAL CREAM [sMTS Dual HA SUN BLOCK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID
Trial: NCT02383511
Drug: SMT C1100
RxNorm normalized name: ZINC OXIDE 2.94 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g / OCTINOXATE 7 g in 100 g TOPICAL CREAM [sMTS Dual HA SUN BLOCK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID
Trial: NCT02383511
Drug: SMT C1100
RxNorm normalized name: ZINC OXIDE 2.94 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g / OCTINOXATE 7 g in 100 g TOPICAL CREAM [sMTS Dual HA SUN BLOCK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID
Trial: NCT02577003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to ipragliflozin tablet administered orally
Trial: NCT02210819
Drug: Recommended VTE pharmacological treatments according to international guidelines
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort participants are classified as Standard of care patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine.
Trial: NCT01179776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v saline
Trial: NCT01179776
Drug: Ilomedin and standard low dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02838537
Drug: Exposure to Triptan
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01227408
Drug: doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin 20mg/m2 weekly x 12 wks, cyclophosphamide 50 mg PO qd x 12 wks, methotrexate 2.5 mg PO bid d1,2 wkly x 12. One week later paclitaxel poliglumex 135mg/m2 IV every 3 wks plus capecitabine 825 mg/m2 PO bid x 14days x 4 cycles
Trial: NCT04096573
Drug: LC51-0255
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC51-0255
Trial: NCT04096573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00787072
Drug: AZD8075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, the starting dose will be 7 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits.
Trial: NCT00787072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension
Trial: NCT00747318
Drug: SKP FlutiForm HFA pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total daily dose of 500 microgram fluticasone propionate and 20 microgram formoterol fumarate.
Trial: NCT02229578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
Trial: NCT01327612
Drug: Modified FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m² administered as a 2-hour intravenous (IV) infusion on day 1 and leucovorin 400 mg/m² racemate or 200 mg/m² levo-leucovorin administered as a 2-hour infusion on day 1, followed by a loading dose of 5-fluorouracil (5-FU) 400 mg/m² IV bolus administered on day 1, then 5-FU 2400 mg/m² via ambulatory pump administered for a period of 46 to 48 hours every 14 days.
Trial: NCT01646385
Drug: non-biologic anti-rheumatic drugs
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use as per routine clinical practice (methotrexate, azathioprine, cyclophosphamide, cyclosporine, leflunomide, other)
Trial: NCT02045290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01013142
Drug: MN-221 (Dose Group 1)
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour
Trial: NCT01013142
Drug: MN-221 (Dose Group 2)
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
Trial: NCT01013142
Drug: MN-221 (Dose Group 3)
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour
Trial: NCT04042077
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Powder for solution for infusion 50 mg, TID, for 5 to 14 days
Trial: NCT03004404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02552459
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sufentanil 150μg， intravenous administration during post-operative 72 hours.
Trial: NCT00180713
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40mg od for 1 month, then 80mg od for 11 months
Trial: NCT00180713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily.
Trial: NCT01238536
Drug: Epidural local anesthetic injection
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
Trial: NCT03077620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given a placebo at bedtime for two consecutive nights that they are spending in a research unit.
Trial: NCT01335295
Drug: Flavocoxid
RxNorm normalized name: Flavocoxid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavocoxid capsules TTD 500 mg/die or 1000 mg/die for 1 year
Trial: NCT01100047
Drug: AZD5069
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension
Trial: NCT01100047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension
Trial: NCT00309608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily
Trial: NCT00004430
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01080300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill
Trial: NCT00150618
Drug: SPD503 (1 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00150618
Drug: SPD503 (2 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00150618
Drug: SPD503 (3 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00975221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally following the same tiitration regimen as the experimental arm.
Trial: NCT00150618
Drug: SPD503 (4 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00150618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04358341
Drug: DOXOrubicin Liposome Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m2 ivdrip every 14 days
Trial: NCT04358341
Drug: 5fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m2 iv bolus and 2400 mg/m2 civ 46h every 14 days
Trial: NCT01364402
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline intravenously
Trial: NCT04296747
Drug: induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 240mg, d1; docetaxel 75mg/m2 d1; cisplatin 75mg/m2 d1, q21d, for 2 cycles
Trial: NCT00424567
Drug: Cultured Bone Marrow Tissue
RxNorm normalized name: Sus scrofa bone marrow preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00422734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet taken by mouth once a day for 12 weeks
Trial: NCT04530578
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized Heparin every 8 hours plus Subcutaneous Enoxaparin every 24hours
Trial: NCT01303250
Drug: balanced 6% hydroxyethylstarch 130/0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid administration and optimization based on cardiac output findings during surgery.
Trial: NCT01303250
Drug: balanced crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid administration and optimization based on cardiac output findings during surgery.
Trial: NCT03127670
Drug: Solanum melongena peel extract 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered topically twice daily for 12 weeks
Trial: NCT02688530
Drug: IV Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00763451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
Trial: NCT00727506
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBW 2992 once daily
Trial: NCT00107523
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00953732
Drug: Lesion count
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
Trial: NCT02296892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive control arm
Trial: NCT02342925
Drug: RG1662
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration twice daily
Trial: NCT02254421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match presatovir administered orally or via nasogastric tube
Trial: NCT02690844
Drug: Mucolox® alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mL Mucolox® TID. Mixture swished around mouth for 3 minutes then spat out.
Trial: NCT00544232
Drug: Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF
Trial: NCT02994771
Drug: Lymfactin® [1 x 10E11 vp]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymfactin® \[1 x 10E11 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.
Trial: NCT00450229
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03344068
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedaplatin 80mg/m2 d1+5-fluouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
Trial: NCT00594906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
Trial: NCT01033773
Drug: Antihyperglycemic medication guideline for management of uncontrolled hyperglycemia presenting to the ED using metformin, sulfonylurea and/or insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes medications (including sulfonylureas, metformin and/or insulin) were initiated and/or adjusted at each visit using the intervention algorithm per presenting blood glucose and prior diabetes medications.
Trial: NCT02523690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or enteral, single dose. Oral or enteral, single dose two days later
Trial: NCT00245960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01791972
Drug: Placebo Spiromax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) delivering placebo to match the experimental drug. Participants received one dose of two inhalations.
Trial: NCT00245375
Drug: Tylenol #3
RxNorm normalized name: Tylenol #3 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00245375
Drug: Combination Tylenol and Ibuprofen
RxNorm normalized name: ibuprofen, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00632502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks.
Trial: NCT00632502
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms
Trial: NCT00570908
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: concurrently
Trial: NCT02193490
Drug: DNase
RxNorm normalized name: DNase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNase 0.1% eye drops four times a day for 8 weeks
Trial: NCT02193490
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug vehicle eye drops four times a day for 8 weeks
Trial: NCT03694977
Drug: MCS110/PDR001 combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCS110 7.5mg/kg iv since 1st cycle PDR001 300 mg iv since 2nd cycle Q 3weeks
Trial: NCT01129336
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients with no bone metastasis (n=150) will receive Standard therapy plus Zoledronic acid administration 4 mg IV monthly during Months 1-18.
Trial: NCT03525574
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) tablet for oral administration.
Trial: NCT01254565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously at the end of hemodialysis
Trial: NCT03989635
Drug: QAW039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAW039 450mg
Trial: NCT00220623
Drug: antidepressant medications, flexible drug choice
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04262206
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
Trial: NCT01301599
Drug: alpha blocker monotherapy
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha blocker monotherapy group
Trial: NCT01301599
Drug: 5 alpha reductase inhibitor monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 alpha reductase inhibitor monotherapy
Trial: NCT02579772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.
Trial: NCT02643147
Drug: Conventional Strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage of loop diuretics is done according to the presence of symptoms and signs of systemic congestion and current recommendations
Trial: NCT04058834
Drug: NNC0385-0434
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers and patients will receive one injection s.c. (subcutaneously, under the skin)
Trial: NCT04058834
Drug: Placebo (NNC0385-0434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers will receive one injection s.c.
Trial: NCT00707499
Drug: BMS747158
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration.
Trial: NCT00379769
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea (SU) maximum permitted daily dose
Trial: NCT01115686
Drug: Branched-chain aminoacids
RxNorm normalized name: Machilus thunbergii branch extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched-chain aminoacids will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day. Every capsule containing 375 milligrams of branched-chain aminoacids.~The treatment will last 3 weeks.
Trial: NCT01115686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day.~The treatment will last 3 weeks.
Trial: NCT00837590
Drug: Chronic salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive 2 months of treatment with 4 gram/day of oral salsalate divided into 3 doses.
Trial: NCT00837590
Drug: Acute Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single oral dose of 2 gram of oral salsalate
Trial: NCT00486668
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 IV every 21 days for cycles 1-4
Trial: NCT00486668
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 IV every 21 days for cycles 1-4
Trial: NCT01986114
Drug: SM-13496
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00791921
Drug: Placebo of CDP870
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given every 2 weeks until Week22 (SC)
Trial: NCT00760513
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 grammes daily, oral capsule (olive oil)
Trial: NCT00171236
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01053247
Drug: 0416
RxNorm normalized name: CATH SET,FOLEY CATH 16FR 5ML B#300416A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0416 test product applied twice daily for 2 weeks
Trial: NCT01053247
Drug: Vehicle of 0416 test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of 0416 test product applied twice daily for 2 weeks
Trial: NCT04672512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching CORT125329 lipid capsule formulation 1 or 2 for oral administration
Trial: NCT01864863
Drug: HGP1206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Bosentan 125 mg tablet
Trial: NCT00717678
Drug: Prograf-XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02061878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
Trial: NCT00068432
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral celecoxib twice daily on days 1-28. Courses repeat every 4 weeks.
Trial: NCT00645177
Drug: Placebo for ABT-869
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
Trial: NCT00444275
Drug: Xolaam®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed